Rakesh Jhunjhunwala’s Children’s Trusts Gain Rs 1,53,71,53,640 as Pharma Stock Rallies on USFDA Approval for USD 500 Million US Market Opportunity
Join Us
Follow Us
One of the key highlights of Concord Biotech is its strong Jhunjhunwala family shareholding. The family holds a combined 24.1 per cent stake in the company, amounting to 25,199,240 shares. The holding is divided across three discretionary trusts: Aryaman Jhunjhunwala Discretionary Trust: 8.03 per cent, or 8,399,754 shares, Aryavir Jhunjhunwala Discretionary Trust: 8.03 per cent, or 8,399,754 shares ,Nishtha Jhunjhunwala Discretionary Trust: 8.03 per cent, or 8,399,732 shares.
✨ Key Takeaways
Indian equity benchmarks traded in positive territory on Wednesday, with the Nifty hovering around the 23,350 mark and the Sensex holding above 74,350. Amid the broader market strength, stock-specific action remained strong, with Concord Biotech share price over 5 per cent in early trade on Wednesday, June 10, 2026.
Concord Biotech share price rose by more than 5 per cent to around Rs 1,340, marking the stock’s highest level since February 9, 2026.
Jhunjhunwala Family Holds 24.1 Per Cent Stake
One of the key highlights of Concord Biotech is its strong Jhunjhunwala family shareholding. The family holds a combined 24.1 per cent stake in the company, amounting to 25,199,240 shares.
The holding is divided across three discretionary trusts:
- Aryaman Jhunjhunwala Discretionary Trust: 8.03 per cent, or 8,399,754 shares
- Aryavir Jhunjhunwala Discretionary Trust: 8.03 per cent, or 8,399,754 shares
- Nishtha Jhunjhunwala Discretionary Trust: 8.03 per cent, or 8,399,732 shares
Late Shri Rakesh Jhunjhunwala, often referred to as India’s Warren Buffett, along with his wife, had originally invested in the Ahmedabad-based biopharma company in 2004.
The family retained its entire 24.1 per cent stake when Concord Biotech went public through its Initial Public Offering. After the company’s listing, the late Big Bull’s estate plan was legally executed, and the block of 25,199,240 shares was transferred into three separate child-specific discretionary trusts for a clear and equal distribution of equity ownership.
Rs 153.72 Crore Notional Gain in a Day
With Concord Biotech share price gaining around Rs 61 per share on Wednesday, the Jhunjhunwala family’s combined holding saw a notional gain of nearly Rs 153.72 crore (Rs 1,53,71,53,640) in early trade on June 10.
The calculation is based on the family’s total holding of 25,199,240 shares and the per-share gain of Rs 61.
USFDA Approval Drives Sentiment
The rally came after Concord Biotech informed the exchanges that it had received approval from the US Food and Drug Administration for its ANDA for Tofacitinib Tablets in 5 mg and 10 mg strengths.
Tofacitinib tablets are used for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately to severely active ulcerative colitis. The drug is also indicated for active polyarticular course juvenile idiopathic arthritis.
According to market estimates, the US market opportunity for Tofacitinib Tablets across both strengths is around USD 500 million. The approval strengthens Concord Biotech’s product portfolio and gives the company an opportunity to expand further in the US and other international markets.
Disclaimer: The article is for informational purposes only and not investment advice.